Brentuximab Vedotin Plus Ibrutinib in Relapsed and Refractory Hodgkin Lymphoma

DISCUSSION: The combination of BV and ibrutinib was active in r/r HL; however, given significant toxicity, it cannot be recommended for future development.PMID:38693037 | DOI:10.1016/j.clml.2024.03.013

Source: Clinical Lymphoma and Myeloma - May 1, 2024 Category: Cancer & Oncology Authors: Matthew Mei Ni-Chun Tsai Joycelynne Palmer Saro Armenian Robert Chen Steven Rosen Stephen Forman Leslie Popplewell Larry Kwak Peter Martin Kami Maddocks David Bond Alex F Herrera Source Type: research